Answers are grounded in this paper and cite their sources.
Chronic kidney disease (CKD) is a leading cause of feline morbidity, and few interventions beyond dietary and supportive care alter its course. Hybrosomes (the manufacturer’s designation for extracellular vesicle [EV]–liposome hybrid vesicles) are a proposed cell-free renal therapy with no clinical data in cats. We conducted an open-label, uncontrolled pilot case series of ten client-owned cats with IRIS stage 2–4 CKD (staged by serum creatinine, Cr) that received four intravenous hybrosome infusions, administered once weekly, each preceded by methylprednisolone sodium succinate, in addition to standard care that continued or adjusted fluid therapy. Blood urea nitrogen (BUN) and Cr were measured weekly to week 4; renal Doppler indices and left ventricular global longitudinal strain (LV GLS) were assessed at baseline and week 4 in seven cats. For the two principal renal outcomes (baseline to week 4, Holm-adjusted across the two outcomes), median BUN decreased from 94 to 47 mg/dL (adjusted p = 0.012) and median Cr from 4.6 to 2.7 mg/dL (adjusted p = 0.020); in exploratory weekly comparisons adjusted across four time points, the week-4 Cr change had an adjusted p of 0.078. Six cats showed a reduction in serum Cr of ≥25% and six shifted to a lower creatinine-based IRIS category, whereas none shifted to a higher category. However, the rapid early falls in two cats (cats 1 and 3) may have reflected a prerenal or acute-on-chronic component. After excluding these cats, the decrease in serum Cr was no longer statistically significant (n = 8, p = 0.078). LV GLS became numerically more negative in all seven cats (unadjusted p = 0.016), but the change was small in six of the seven cats (0.7–2.0 percentage points) and the 95% confidence interval of the mean difference included zero. Four cats developed transient nausea or salivation during or after infusion; isolated haematological abnormalities (thrombocytopenia in two cats, leukocytosis in one and falls in haemoglobin in several) were also recorded and could not be attributed to, or excluded from, the treatment. Because the series was uncontrolled and standard therapy, including fluid therapy and methylprednisolone sodium succinate premedication, were continued, these findings are hypothesis-generating and do not establish efficacy; placebo-controlled trials with longer follow-up would be needed to test efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Algan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: